CURE5 Foundation
↗New York, USA
CURE5 Foundation is a parent-led, 501(c)(3) non-profit organization focused on finding a cure for CDKL5 Deficiency Disorder (CDD). The foundation funds and facilitates research, prioritizing rapid drug repurposing, AI-driven drug discovery, and translational science to move potential treatments from the lab to patients efficiently.
By collaborating with academic institutions, biotech companies, and research labs, CURE5 aims to bridge the gap between theoretical research and clinical application. Their initiatives include high-throughput screening in brain organoids, AI-powered knowledge engines for research literature, and the development of novel therapeutic compounds.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Rare Disease / Neurodevelopmental Disorders
SIZE & FINANCIALS
Employees:1-50
Founded:2023
Ownership:nonprofit
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery/Preclinical
Modalities:Small molecule, Gene therapy, AI-driven drug discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Ulysses Neuroscience (Angel Compounds development), BrainStorm Therapeutics (Organoid screening), Unravel Biosciences (AI-driven RNA analysis)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Andreas Borg - Co-Founder
Ana Borg - Co-Founder
Lili Hasse - Co-Founder
LINKS
Website:cure5.foundation
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of CURE5 Foundation and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with CURE5 Foundation. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.